Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

To treat with curative intent or modify disease?

Mary Eapen

Blood (2023) 141 (1): 4–5.

https://doi.org/10.1182/blood.2022017792

Published: 2023

Journal Articles

Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation

Andrew St. Martin, Kyle Hebert, Arnaud Serret-Larmande, Vianney Jouhet, Emily Hughes, Jason Paul Stedman, Thomas DeSain, Danielle Pillon, Jessica Lyons Carpenter, Patricia Steinert, Paul Avillach, Mary Eapen

Blood (2021) 138 (Supplement 1): 410.

https://doi.org/10.1182/blood-2021-150912

Published: 2021

Journal Articles

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Blood (2021) 138 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2021-145527

Published: 2021

Journal Articles

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)

Ashley V Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A. Pulsipher, Mary Eapen, Jim A. Connelly, Catherine M. Bollard, Sung-Yun Pai, Christine N. Duncan, Leslie S Kean, K. Scott Baker, Lauri S Burroughs, Jeffrey R. Andolina, Michael B Jordan, Tsz-Kwong Man, Carl E. Allen, Rebecca A. Marsh

Blood (2021) 138 (Supplement 1): 748.

https://doi.org/10.1182/blood-2021-145629

Published: 2021

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

Muna Qayed, Kwang Woo Ahn, Carrie L. Kitko, Mariam H. Johnson, Nirali N. Shah, Christopher Dvorak, Karin Mellgren, Brian D. Friend, Michael R. Verneris, Wing Leung, Jacek Toporski, John Levine, Joseph Chewning, Alan Wayne, Urvi Kapoor, Brandon Triplett, Kirk R. Schultz, Gregory A. Yanik, Mary Eapen

Blood (2021) 137 (7): 983–993.

https://doi.org/10.1182/blood.2020009342

Published: 2021

Journal Articles

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent Logan, Joseph H. Antin, Peter Dawson, Steven Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John M. Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein

Blood (2021) 137 (3): 420–428.

https://doi.org/10.1182/blood.2020007535

Published: 2021

Includes: Supplemental data

Journal Articles

Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Rebecca A. Marsh, Soyoung Kim, Kyle Hebert, Christopher C. Dvorak, MD, Victor Aquino, MD, K. Scott Scott Baker, MD MS, Deepak Chellapandian, MD, Blachy Davila, MD, Christine Duncan, MD, Michael J. Eckrich, MD MPH, George E. Georges, MD, Timothy S. Olson, MD PhD, Michael A Pulsipher, MD, Shalini Shenoy, MD, Elizabeth Stenger, MD, Mark Vander Lugt, MD, Lolie C. Yu, MD, Andrew Gennery, MD, Mary Eapen, MBBS, MS

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139930

Published: 2020

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Ruta Brazauskas, Graziana M. Scigliuolo, Hai-Lin Wang, Barbara Cappelli, Annalisa Ruggeri, Courtney D. Fitzhugh, Jane S. Hankins, Julie Kanter, Joerg J. Meerpohl, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, Mark C. Walters, John E. Wagner, John F. Tisdale, Eliane Gluckman, Mary Eapen

Blood (2020) 136 (5): 623–626.

https://doi.org/10.1182/blood.2020005687

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507

Adetola A. Kassim, MDMS, Mark C. Walters, MD, Mary Eapen, MBBS, MS, Brianne Allison, MS, Adam M. Mendizabal, MS, Robert A. Brodsky, MD, Michael R. DeBaun, MDMPH

Blood (2019) 134 (Supplement_1): 802.

https://doi.org/10.1182/blood-2019-126321

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503

Mary Eapen, MBBS, MS, Donna S Neuberg, ScD, Adam M. Mendizabal, MS, Kristen E. Stevenson, MS, Joseph H. Antin, MD, Nancy DiFronzo, PhD, Fuad A El Rassi, MD, Premal Lulla, MBBS, Edmund K. Waller, PhDMD, Jamie Garrison, Shannon Smith, MSN, Keith Sullivan, MD, Mark C. Walters, MD, Lakshmanan Krishnamurti, MD

Blood (2019) 134 (Supplement_1): 4592.

https://doi.org/10.1182/blood-2019-126793

Published: 2019

Journal Articles

Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR

Jason Dehn, Stephen Spellman, Carolyn K. Hurley, Bronwen E. Shaw, Juliet N. Barker, Linda J. Burns, Dennis L. Confer, Mary Eapen, Marcelo Fernandez-Vina, Robert Hartzman, Martin Maiers, Susana R. Marino, Carlheinz Mueller, Miguel-Angel Perales, Raja Rajalingam, Joseph Pidala

Blood (2019) 134 (12): 924–934.

https://doi.org/10.1182/blood.2019001212

Published: 2019

Journal Articles

Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey

Blood (2018) 132 (Supplement 1): 308.

https://doi.org/10.1182/blood-2018-99-111152

Published: 2018

Journal Articles

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Blood (2018) 132 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2018-99-110814

Published: 2018

Journal Articles

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies

Blood (2018) 132 (13): 1438–1451.

https://doi.org/10.1182/blood-2018-01-828277

Published: 2018

Includes: Supplemental data

Journal Articles

Surviving childhood cancer: a sobering story

Mary Eapen

Blood (2018) 131 (24): 2603–2604.

https://doi.org/10.1182/blood-2018-05-847517

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 50 Years or Older with Severe Aplastic Anaemia: Results from the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research

Blood (2017) 130 (Supplement 1): 2446.

https://doi.org/10.1182/blood.V130.Suppl_1.2446.2446

Published: 2017

Journal Articles

Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant

Blood (2017) 130 (Suppl_1): 851.

https://doi.org/10.1182/blood.V130.Suppl_1.851.851

Published: 2017

NARROW

To treat with curative intent or modify disease?

Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503

Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR

Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies

Surviving childhood cancer: a sobering story

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 50 Years or Older with Severe Aplastic Anaemia: Results from the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only